Loading
Loading
Cognitive & Nootropic · 10mg
Choose dose
Janoshik-tested · 10 vials per kit
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide studied in preclinical research for its sleep-regulatory and neuromodulatory properties. Research has examined its potential to promote slow-wave delta sleep, modulate stress hormone responses including ACTH and cortisol, reduce oxidative stress, and exhibit antioxidant activity. Studies have also explored potential analgesic and normotensive effects.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
DSIP
Delta Sleep-Inducing Peptide
DSIP (Delta Sleep-Inducing Peptide) is a synthetic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1974 from the cerebral venous blood of sleeping rabbits by Schoenenberger et al. at the University of Basel. Despite the name, research has shown it modulates sleep architecture and neuroendocrine function broadly rather than simply inducing sleep, with particularly interesting effects on HPA axis regulation and antioxidant systems.
DSIP modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing ACTH and cortisol release — an effect relevant to stress-related sleep disruption. It enhances slow-wave (delta) sleep while reducing sleep fragmentation. Antioxidant activity (reducing lipid peroxidation and protecting mitochondrial membranes) has been documented in multiple tissue types. DSIP also interacts with opioid receptor sensitivity, with antagonistic effects at low doses on opioid tolerance development.
Research areas include sleep architecture optimisation, HPA axis dysregulation, chronic stress, cancer-related pain and insomnia, opiate withdrawal symptom mitigation, and menopausal symptom management (Russian clinical studies). Animal longevity studies showed that chronic DSIP administration extended mean and maximum lifespan in mice with reduction in spontaneous tumour incidence.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
